The pediatric sepsis biomarker risk model: Potential implications for sepsis therapy and biology

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 7, 2014, Pages 809-816

  Alder, Matthew N ^a,b   Lindsell, Christopher J ^b   Wong, Hector R ^a,b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Pediatric; PERSEVERE; Risk stratification; Sepsis

Indexed keywords

GRANZYME B; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70KDA 1B; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTROPHIL COLLAGENASE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GRANZYME;

ADAPTIVE IMMUNITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MODEL; MORTALITY; PEDIATRIC SEPSIS BIOMARKER RISK MODEL; PROBABILITY; PROTEIN BLOOD LEVEL; REVIEW; SEPSIS; ADULT; BLOOD; CHILD; DECISION TREE; INTENSIVE CARE UNIT; PROGNOSIS; RISK FACTOR; THEORETICAL MODEL;

ADULT; BIOLOGICAL MARKERS; CHEMOKINE CCL3; CHEMOKINE CCL4; CHILD; DECISION TREES; GRANZYMES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTENSIVE CARE UNITS, PEDIATRIC; INTERLEUKIN-1ALPHA; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 8; MODELS, THEORETICAL; PROGNOSIS; RISK FACTORS; SEPSIS;

EID: 84902504618     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.912131     Document Type: Review

References (59)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348(16):1546-54
2. Hanna W, Wong HR. Pediatric sepsis: challenges and adjunctive therapies. Crit Care Clin 2013;29(2):203-22
3. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420(6917):885-91
4. Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev 2013; 93(3):1247-88
5. Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock 2013; 40(5):358-65
6. Wong HR, Salisbury S, Xiao Q, et al. The pediatric sepsis biomarker risk model. Crit Care 2012;16(5):R174
7. Wong HR, Weiss SL, Giuliano JS Jr, et al. Testing the prognostic accuracy of the update pediatric sepsis biomarker risk model. PLoS One 2014;9:e86242
8. Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011;12(2):165-73
9. Wong HR. Genome-wide expression profiling in pediatric septic shock. Pediatr Res 2013;73(4 Pt 2):564-9
10. Wong HR, Lindsell CJ, Pettila V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 2014;42(4):781-9
11. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003;193:31-8
12. Napoli AM, Fast LD, Gardiner F, et al. Increased granzyme levels in cytotoxic T lymphocytes are associated with disease severity in emergency department patients with severe sepsis. Shock 2012;37(3):257-62
13. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006;6(11):813-22
14. Freishtat RJ, Natale J, Benton AS, et al. Sepsis alters the megakaryocyte-platelet transcriptional axis resulting in granzyme B-mediated lymphotoxicity. Am J Respir Crit Care Med 2009;179(6):467-73
15. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 2005;62(6):670-84
16. Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006;5(22):2592-601
17. Jacquier-Sarlin MR, Fuller K, Dinh-Xuan AT, et al. Protective effects of hsp70 in inflammation. Experientia 1994; 50(11-12):1031-8
18. Jaattela M, Wissing D, Bauer PA, Li GC. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J 1992;11(10):3507-12
19. Luong M, Zhang Y, Chamberlain T, et al. Stimulation of TLR4 by recombinant HSP70 requires structural integrity of the HSP70 protein itself. J Inflamm (Lond) 2012;9:11
20. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008;8(4):279-89
21. McConnell KW, Fox AC, Clark AT, et al. The role of heat shock protein 70 in mediating age-dependent mortality in sepsis. J Immunol 2011;186(6):3718-25
22. Bruemmer-Smith S, Stuber F, Schroeder S. Protective functions of intracellular heat-shock protein (HSP) 70-expression in patients with severe sepsis. Intensive Care Med 2001;27(12):1835-41
23. Ziegler TR, Ogden LG, Singleton KD, et al. Parenteral glutamine increases serum heat shock protein 70 in critically ill patients. Intensive Care Med 2005;31(8): 1079-86
24. Pittet JF, Lee H, Morabito D, et al. Serum levels of Hsp 72 measured early after trauma correlate with survival. J Trauma 2002;52(4):611-17. discussion 617
25. Wheeler DS, Fisher LE Jr, Catravas JD, et al. Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med 2005;6(3):308-11
26. Rider P, Carmi Y, Voronov E, Apte RN. Interleukin-1a. Semin Immunol 2013;25(6): 430-8
27. McCarthy DA, Clark RR, Bartling TR, et al. Redox control of the senescence regulator interleukin-1alpha and the secretory phenotype. J Biol Chem 2013; 288(45):32149-59
28. Joosten LA, Van De Veerdonk FL, Vonk AG, et al. Differential susceptibility to lethal endotoxaemia in mice deficient in IL-1alpha, IL-1beta or IL-1 receptor type I. APMIS 2010;118(12):1000-7
29. Harada A, Mukaida N, Matsushima K. Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today 1996;2(11):482-9
30. Miyoshi T, Yamashita K, Arai T, et al. The role of endothelial interleukin-8/NADPH oxidase 1 axis in sepsis. Immunology 2010; 131(3):331-9
31. Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 2013;17(5):R253
32. Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008;178(3):276-82
33. Calfee CS, Thompson BT, Parsons PE, et al. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med 2010;38(6):1436-41
34. Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 1996;59(1):61-6
35. Standiford TJ, Kunkel SL, Lukacs NW, et al. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol 1995;155(3):1515-24
36. Kobayashi M, Takahashi H, Sanford AP, et al. An increase in the susceptibility of burned patients to infectious complications due to impaired production of macrophage inflammatory protein 1 alpha. J Immunol 2002;169(8):4460-6
37. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002;13(6): 455-81
38. O'Grady NP, Tropea M, Preas HL 2nd, et al. Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. J Infect Dis 1999;179(1):136-41
39. Lahrtz F, Piali L, Spanaus KS, et al. Chemokines and chemotaxis of leukocytes in infectious meningitis. J Neuroimmunol 1998;85(1):33-43
40. Okamoto T, Akaike T, Suga M, et al. Activation of human matrix metalloproteinases by various bacterial proteinases. J Biol Chem 1997;272(9): 6059-66
41. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007;82(6):1375-81
42. Solan PD, Dunsmore KE, Denenberg AG, et al. A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med 2012;40(2):379-87
43. Lauhio A, Hastbacka J, Pettila V, et al. Serum MMP-8,-9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 2011;64(6):590-4
44. Vandenbroucke RE, Dejonckheere E, Van Lint P, et al. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J Neurosci 2012;32(29):9805-16
45. Wynn J, Cornell TT, Wong HR, et al. The host response to sepsis and developmental impact. Pediatrics 2010;125(5):1031-41
46. Barsness KA, Bensard DD, Partrick DA, et al. IL-1beta induces an exaggerated proand anti-inflammatory response in peritoneal macrophages of children compared with adults. Pediatr Surg Int 2004;20(4):238-42
47. Barsness KA, Bensard DD, Partrick DA, et al. Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. J Pediatr Surg 2004;39(6):912-15. discussion 912-5
48. Mariotti M, Castiglioni S, Bernardini D, Maier JA. Interleukin 1 alpha is a marker of endothelial cellular senescent. Immun Ageing 2006;3:4
49. Kumar S, Vinci JM, Millis AJ, Baglioni C. Expression of interleukin-1 alpha and beta in early passage fibroblasts from aging individuals. Exp Gerontol 1993;28(6): 505-13
50. Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012;16(3):R112
51. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862-74
52. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138-50
53. Wong HR, Weiss SL, Giuliano JS Jr, et al. The temporal version of the pediatric sepsis biomarker risk model. PLoS One 2014;9(3): e92121
54. Wynn JL, Neu J, Moldawer LL, Levy O. Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J Perinatol 2009;29(2):79-88
55. Abulebda K, Cvijanovich NZ, Thomas NJ, et al. Post-ICU Admission Fluid Balance and Pediatric Septic Shock Outcomes: a Risk-Stratified Analysis. Crit Care Med 2014;42(2):397-403
56. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab') 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32(11):2173-82
57. Mussap M, Noto A, Cibecchini F, Fanos V. The importance of biomarkers in neonatology. Semin Fetal Neonatal Med 2013;18(1):56-64
58. Noto A, Mussap M, Fanos V. Is H NMR metabolomics becoming the promising early biomarker for neonatal sepsis and for monitoring the antibiotic toxicity? J Chemother 2013. [Epub ahead of print]
59. Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care Med 2013;187(9):967-76